BNT162b2 Induces Robust Cross-Variant SARS-CoV-2 Immunity in Children

Researchers observed delayed induction and reduced magnitude of vaccine-induced antibody titers in children 5-11 years receiving two doses of the age-recommended 10 μg dose of the Pfizer SARS-CoV-2 BNT162b2 vaccine, compared to adolescents or adults receiving the 30 μg dose.